Related references
Note: Only part of the references are listed.Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial
James B. Bussel et al.
LANCET (2009)
Novel thrombopoietic agents - A review of their use in idiopathic thrombocytopenic purpura
Roberto Stasi et al.
DRUGS (2008)
New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura
David J. Kuter
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura:: a double-blind randomised controlled trial
David J. Kuter et al.
LANCET (2008)
Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura
James B. Bussel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist
CL Erickson-Miller et al.
EXPERIMENTAL HEMATOLOGY (2005)
Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand
B Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro
M Chang et al.
BLOOD (2003)
Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor
RL Basser et al.
BLOOD (2002)
Thrombocytopenia caused by the development of antibodies to thrombopoietin
JZ Li et al.
BLOOD (2001)
Share Paper
